Intensive lifestyle intervention focusing on weight loss may reduce cardiovascular events in selected type 2 diabetes patients yet have a detrimental treatment effect in some, according to recent research.
Intensive lifestyle intervention focusing on weight loss may reduce cardiovascular events in selected type 2 diabetes patients yet have a detrimental treatment effect in some, according to recent research.
The study, published by Diabetes Care, investigated the presence of heterogeneity of treatment effect (HTE) of an intensive lifestyle intervention in order to measure the efficacy on the occurrence of major cardiovascular events (MACE) in patients with type 2 diabetes who are also overweight or obese.
The researchers used data from the Action for Health in Diabetes trial and assessed 4901 participants. Additionally, a penalized Cox regression model was utilized to predict the treatment effect of intensive lifestyle intervention for the risk of MACE. Hazard ratios were calculated and the absolute risk change of the predicted treatment effect were used to confirm the model’s efficacy between quartiles, according to the study.
The results revealed that in quartile 1 of predicted treatment effect, with the highest predicted risk reduction, the researchers found that there was a significant treatment benefit of intensive lifestyle intervention (hazard ratio [HR] 0.64; 95% CI 0.49—0.83). However, in quartiles 2 and 3 there was no effect from the treatment. There was a detrimental effect in quartile 4 (HR 1.37; 95% CI 1.09–1.73).
The study also noted that demographics, medical history, physical examination, and laboratory values were associated with the level of treatment effect.
“This post hoc analysis of the Look AHEAD trial showed that an intensive lifestyle intervention aimed at weight loss may reduce cardiovascular events in selected patients but may have a detrimental treatment effect in others,” concluded the authors.
Reference
Vries T, Dorresteijn J, Graaf Y, et al. Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial [published online September 2019]. Diabetes Care. doi.org/10.2337/dc19-0776.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs
September 20th 2024The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin costs for patients, prompting renewed calls for PBM reform.
Read More
Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes
September 5th 2024This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.
Read More